HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World data: takhzyro cuts HAE attacks in saudi patients
Disease control Recruiting nowThis study looks at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro for at least 6 months to prevent swelling attacks. Researchers want to see if the drug reduces disease activity and improves quality of life in real-wor…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New hope for kids with rare swelling disorder: drug trial targets attacks
Disease control Recruiting nowThis study tests a medicine called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and helps reduce the number of swelling attacks. Participants receive the drug an…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
Daily pill could stop painful swelling attacks for HAE patients
Disease control Recruiting nowThis study tests a once-daily pill called deucrictibant to prevent sudden, painful swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The goal is to see if the drug is safe and effective over the long term. About 170 participants will take the pill dai…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 17, 2026 06:46 UTC
-
Kids with rare swelling disorder get continued access to promising preventive drug
Disease control AVAILABLEThis program provides ongoing access to the study drug garadacimab for children aged 2 to 11 with hereditary angioedema (HAE) who completed a previous study and had good results. The goal is to keep preventing HAE attacks in these children. Only those who responded well and had n…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: CSL Behring • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who finished a previous phase 3 trial of ADX-324. It aims to see if the drug is safe and can prevent swelling attacks over a longer period. About 90 participants will receive additional doses of ADX-324 and be monitored fo…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New shot could stop HAE attacks in their tracks
Disease control Recruiting nowThis study tests a new medicine called navenibart to see if it can prevent the sudden, painful swelling attacks that people with hereditary angioedema (HAE) experience. About 145 adults and teenagers with HAE type 1 or 2 will receive either navenibart or a placebo injection for 6…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Real-World data to reveal how a swelling drug helps kids
Knowledge-focused Recruiting nowThis study reviews medical records of 40 children aged 2 to 12 with hereditary angioedema (HAE) who have taken lanadelumab (Takhzyro) to prevent swelling attacks. Researchers will measure how many children stay attack-free and track treatment patterns, safety, and healthcare use.…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 11, 2026 20:49 UTC